• Senior Research Associate, Cellular Therapy (AgenTus)

    Job Locations US-MA-Lexington
    Job ID
  • Overview

    AgenTus (Lexington, MA) is seeking a highly talented, innovative, and motivated Senior Research Associate to join the Cellular Therapy group. The selected candidate will work as part of an integrated research team focused on discovering and validating novel cell therapeutics including chimeric antigen receptors (CAR-Ts) and T cell receptors (TCRs). Come join our innovative team and work at an exciting company in the field of adoptive cell therapy!



    The successful candidate will work as part of a core team to create and characterize targeting molecules, including CARs and TCRs, that will enable the development of novel cellular therapeutics. The candidate will be expected to work independently and as part of a cross-functional group to design and generate DNA constructs and viral vectors as well as to optimize higher-throughput processes for functionally testing the biological activity of new molecules. Work will include plasmid construction, molecular engineering, viral vector production and cell based immunologic assays. The candidate should have the ability to independently troubleshoot technical issues and develop optimized processes for common tasks. Specific knowledge of Gibson Assembly cloning procedures and/or flow cytometry methods is a plus.





    • A BS or MS in molecular/cellular biology, immunology or related field with a minimum of 8 years of research experience.
    • Experience with cellular therapy processes including molecular cloning, gene delivery into primary immune cells and immunology-based assays is preferred.
    • Ability to interact with a diverse group of scientists in a collaborative environment.
    • He/she should enjoy independently designing experiments & executing project tasks
    • Excellent analytical and communication skills are important for this position


    Sorry the Share function is not working properly at this moment. Please refresh the page and try again later.
    Share on your newsfeed